IDMO Cellares and TScan Therapeutics will work collectively to guage automated scientific manufacturing of TSC-101, which is TScan’s lead TCR-T remedy candidate for sufferers with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
TSC-101 is designed to deal with residual illness and forestall relapse in sufferers with AML and MDS present process allogeneic hematopoietic cell transplantation (allo-HCT). The remedy candidate makes use of a gene modification strategy to engineer T cells from a wholesome donor right into a patient-specific cell remedy product. As TScan advances TSC-101 towards a pivotal trial, which is predicted to start within the second quarter of 2026, the corporate is evaluating Cellares’ automated manufacturing platform as a scalable and economical path to future business demand.
Beneath the settlement, Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle, its end-to-end manufacturing platform, and the Cell Q, its automated high quality management and launch testing system. These closed-system, absolutely automated workflows are designed to scale back course of variability, reduce labor depth, and allow constant execution throughout runs and geographies, in accordance with a Cellares official.
“As we put together for the initiation of our pivotal research of TSC-101 this quarter, we’re growing our efforts for business readiness. Establishing a scalable and cost-efficient manufacturing technique is a vital element. Cellares’ absolutely automated Cell Shuttle platform represents a promising strategy to automating and scaling cell remedy manufacturing, with the potential to scale back handbook processes and remove capability constraints,” mentioned Ray Lockard, chief manufacturing and high quality officer of TScan Therapeutics.
“Via this analysis, we purpose to find out how this know-how may strengthen our long-term manufacturing community and assist broader affected person entry, supporting our purpose of delivering transformative therapies to sufferers as effectively and reliably as potential.”
“Sufferers with AML or MDS who stay susceptible to relapse following transplant characterize precisely the sort of underserved inhabitants that automated manufacturing was designed to achieve,” added Fabian Gerlinghaus, co-founder and CEO of Cellares. “Bringing automation to a late-stage program like TSC-101, with its wholesome donor-derived however patient-specific manufacturing mannequin, is the sort of problem the Cell Shuttle and Cell Q have been constructed for, and we consider it represents the manufacturing economics any developer might want to attain a inhabitants of this scale.”
The settlement provides TCR-engineered T cell therapies to Cellares’ portfolio of automated cell remedy modalities, which incorporates CAR T cell therapies, hematopoietic stem cell packages, and autologous progenitor T cell therapies.
